Post on 04-Aug-2020
TECHNOLOGY TRANSFER
3
Protection of results?
Cooperation
with 3th parties? Workshops , seminars…?
Medical devices,
serious games,
other tools…
Funding ?
VALORISATION
4
Protection of results?
Cooperation
with 3th parties? Workshops , seminars…?
Medical devices,
serious games,
other tools…
Funding ?
TECHNOLOGY TRANSFER
Research
Center Partner Company
End users End users End users
Company
Hospital Governmental
organisation
Company Health
insurance
agency
Project
VALORISATION
RESULTS, DELIVERABLES
- Books, publications
- Expertise, reports, knowhow
- Data, algorithm, protocol, excell file
- Game, (software)tool
- Training modules, website, video
- New medical device, new antibodies, new drugs, new
methods, point-of-care testing…
LEAD USERS
- Academic researchers, other Research Centers
- Professionals, doctors, physicotherapists
- Companies, non for profit organisations
- Public services, health organisations
- Policy makers, Standard bodies
- End user organisations, parents/friends-organisations
- End users, patients
VALORISATION STRATEGY
- Publication strategy, press contacts, website strategy
- Further applied research, testing proof of concept
- Workshops, training course
- Embedding in health or education systems
- Consultancy, Service contracts
- Product development, Demonstration, Trials
- Pilot scale, clinical studies
- licensing, spin-offs
FUNDING
CONTRACTS
IP-MANAGEMENT
BUSINESS
DEVELOPMENT
Tech Transfer Office
IOF Project Funding Contract
Management IP Management
Business
Development
Network of Industrial Liaison Units
UGENT TECHTRANSFER
10
Chronic spinal pain
Glucose monitoring for diabetes Diagnosis of osteoporosis
Rotavirus in pigs
Healthcare disabled children
Healthy food choices for children
FUNDING
.
FUNDING
FWO
TBM: applied biomedical research
SBO: strategic basic research
VLAIO
Innovation mandate
Baekeland mandate
EU
RIA: Research innovation action
KIC- health: knowledge innovation community
IOF: Industrial research fund
12
FWO FLEMISH RESEARCH FOUNDATION
13
TBM Toegepast biomedisch onderzoek
what Applied biomedical research with a societal finality – after proof of concept
objective implementation of (new) therapies, diagnostic techniques and preventive methods, which,
without government funding, would not make it to the patient due to a lack of industrial
interest.
Late stage
Project period 2-4 years
Budget Min 250.000 – max 1 million Euro
Partners Research centers with at least a Flemish hospital
Lead users
(gebruikersgroep)
Other hospitals, health organisations, physiotherapist, doctors…
No companies
Filing date 13th March (prefiling) – 21st March (final filing)
Info session: 5th december – UZ Gent (2K3) – contact Lieve Nuytinck
(lieve.nuytinck@ugent.be) or vlaams-federaal@ugent.be (in case UZGent is not involved)
Succes rate: 31%
Applied Biomedical Research (TBM)
TRL 5-6-7 Chronic spinal pain guidelines, manuals, software
programs, workshops, video’s…
Governemental org.
Health care
physiotherapists
User group Project partners
FWO FLEMISH RESEARCH FOUNDATION
15
SBO Strategisch basisonderzoek
what Basic research project
objective innovative research which, if scientifically successful, will create prospects for
economic or societal applications (e.g., a new generation of products, processes,
services…).
Project period 4 years
Budget Approx 2 million Euro
Partners Universities, University hospitals, University colleges, Research centers…
Lead users
(gebruikersgroep)
Economical finality: mainly companies (unless spin-off finality)
Societal finality: mainly societal organisations (health, education, government…)
Filing date September 2019!
lieve.nuytinck@ugent.be and vlaams-federaal@ugent.be and Karen.cure@ugent.be
Succes rate: 18%
Strategic basis research (SBO)
TRL 1-2-3 Healthy food choices Experimental data, guidelines,
manual, book, serious game, board
game, video’s…
Governemental org.
Health care
User group Project partners
schools, kind&gezin…
FLANDERS INNOVATION & ENTREPEURSHIP
17
IM Innovatiemandaat – innovation mandate
what Individual mandate for postdoc
objective postdoctoral researchers who wish to deploy active efforts to achieve the effective
transfer, the exploitation and the utilisation of their research findings. They can either
do this with an existing company or for a future spin-off-company.
Project period 2 years (spin-off) or max 3 years (with company in case of pre-phase: “Fase 1”)
Budget Personal cost of postdoc + max 40.000 euro / year per fte –
company cofinances Phase 2
Partners Research centers (universities…) + company (or non for profit org)
User (partner) The company or the spin-off
Filing date Twice a year: March and September
lieve.nuytinck@ugent.be - vlaams-federaal@ugent.be - Karen.cure@ugent.be (TT)
Succes rate: 40-45%
Innovation mandate - company
TRL 3-4-5 Rotavirus in pigs vaccin
Huvepharma
User Project partners
FLANDERS INNOVATION & ENTREPEURSHIP
19
BAE Baekelandmandaat – Baekeland mandate
what Individual mandate – industrial PhD
objective basic research that – if successful – have clear economic objectives and offers added
value to the company involved in the project.
Project period Min. 4 years – (longer in case of not full time)
Budget Personal cost postdoc + max 40.000 euro / year per fte – company cofinances
Partners Company (or non for profit) + University
User (partner) The company or non for profit organisation
Filing date Twice a year: March and September
lieve.nuytinck@ugent.be - vlaams-federaal@ugent.be - Karen.cure@ugent.be (TT)
Succes rate: 50%
Baekeland mandate - company
TRL 3-4-5 Health care for disabled children Business plan for quality services
User Project partners
Unie-K
EU – HORIZON 2020
21
RIA Research and Innovation action
what EU-project: international research
objective Research to establish new knowledge or explore the feasibility of a new or improved
technology, product, process, service or solution
Project period Up to 4 years
Budget 2 – 5 million Euro per consortium
Partners minimum 3 beneficiaries from 3 different EU Member States
Lead users All kind, including participating partners – Economic + Social Impact
Filing date Depending on the calls (Top-down)
lieve.nuytinck@ugent.be -EU-cel@ugent.be - Sarah.dello@ugent.be – IOF
Succes rate: 12%
EU-Research and Innovation action
TRL 3-4 5 Osteoporosis Clinical validation and
preparation of point-of-care device
Lead Users Project partners
EIT – KIC HEALTH
23
KIC Knowledge Innovation Community
what Thematic community of companies, research centers and universities
objective Innovation: To bring the technology to the market, as a product, service or process
Based on validated technologies that need additional step(s) for upscaling, demonstration, implementation,
Education: to bring up to date knowledge, skills and attitudes to caregivers and entrepreneurs in the health
sector
Entrepreneurship: to business creation program to support healthcare entrepreneurs
Project period Up to 3 years
Budget Education: 50.000 Euro to 1million Euro
Partners mixed consortium, strong industrial representation is evaluated as positive.
minimum 2 EIT Health partners from 2 countries
Lead users Health sector
Filing date Annually
Wouter.desoete@ugent.be - Sarah.dello@ugent.be
Succes rate: 50%
EU-KIC Health (foreign examples)
Lead Users Project partners
Training physiotherapists, entrepreneurs, patients, new techniques, methods…
How to learn to co-create or codesign through patients experience…
Education
Workshops
TRL 5 -6-7-8-9
INDUSTRIAL RESEARCH FUND
25
IOF-projects Industrieel Onderzoeksfonds – Industrial Research Fund
what Proof of concept funding of AUGent-findings with economical finality
objective Bridging the gap between academia and industry
Project period Min 1 year – max 3 years
Budget 25.000 Euro till 650.000 Euro
Partner - Applicant Research groups of AUGent
Lead users An existing company or a spin-off company
Filing date 4 times a year, next deadline: 11th of December 2018
Contact: IOF@ugent.be – ingrid.merchiers@ugent.be
Succes rate: 50%
Come and see us to pitch your ideas: 4 calls / year: March – June – September - December Approaching deadline: December 11th 2018
GRANT WRITING AS A LEARNING EVENT
IOF: industrial research fund
TRL 4-5-6 License or spin-off company
Lead User
Applicant
AUGent-research group
antibody
Point-of-care test
Needle free continuous
monitoring for glucose
CONTRACTS
.
OVERVIEW: AGREEMENTS IN DIFFERENT STAGES OF YOUR RESEARCH
1. NDA (CDA)
2. MTA
3. Services
4. Research
5. License vs. assignment
29
RESEARCH RELATIONSHIPS
30
Time
publication
conferences
contact
NDA
Research agreement
consulting
sponsored research
collaboration
IP generation
MTA
Service agreement
option
license License agreement
Exploitation
spin-off
NDA (OR CDA)?
• formal agreement (mutual or unilateral)
• provides for the exchange of confidential information
• enabling protection of proprietary/confidential information
• identifies scope of ‘confidential information’
(‘non-disclosure agreement’ or ‘confidential disclosure agreement’)
31
MTA
32
• MTA = Material Transfer Agreement
• formal agreement
• governs the exchange of loaned research materials
• Describes the purpose:
for research or evaluation purposes
SERVICE AGREEMENT
33
• formal agreement
• Terms and conditions under which UGent will perform services for a third party
• services based on UGent expertise and available infrastructure
• No IP-creation
• Add margin!
RESEARCH AGREEMENT
34
• formal agreement
• Terms and conditions under which UGent will perform research for a third party
or with a third party
• Intellectual contribution of UGent
• Publication rights
• Ownership on results
Research agreement between University
Hospital and other research partners
Research agreement between UGent
and non for profit organisation
Research agreement between
research partners
Research agreement between
University and company
Joint
ownership
UGent
Ownership
Partner
becomes
owner
36
• Right to exploit:
manufacture & sale of products,
rendering of services
granting licenses to third parties
• IP management
• Limitation of Field, Territory, Timing
• Exclusivity - non exclusivity
• Sublicense
• Transfer of all rights
ASSIGNMENT LICENSE
Preferred by IP owners:
ownership
control
Prefered by investors:
IP becomes asset of assignee
Not affected by bankrupty of
assignor
37
License and/or transfer deal with be established
between UGent and spin-off
License and transfer deal between
UGent and spin-off (Indigo Diabetes)
License deal on game for
game producer, lead users…
IP-MANAGEMENT
.
Patents Trade secrets Copyright
Computer programs
Data bases Trademarks
Models and Designs
Breeders’ Rights Chips Design
DIFFERENT INTELLECTUAL PROPERTY RIGHTS
7 SINS OF THE INVENTOR
1 MAJOR SIN FOR ACADEMICS
OVERVIEW
42
Legal
Right
What for? How? How
long?
Strenghts Weaknesses
Trade secrets Valuable
information not
known to the
public
Reasonable
efforts to keep
secret
Until it is
public
- If secret, perpetual
monopoly
- Any subject matter
- Less expensive
- No formal protection
- Reverse engineering
- Industrial spionage
Trademarks Distinctive
identification of
products or
services
Use and/or
registration
n x 10 y* - Not expensive
- Long time protection if re-
registered
- Easily enforceable
(registered)
- No protection for
underlying methods/
techniques/resources
Copyright Original creative
or artistic forms
Exists
automatically
70 y from
death author
- Not expensive
- Long protection
- No protection for technical
features
Design Design of object Registration 5 years (+
5years)
- Less expensive - No protection for technical
features
Patents New inventions Application and
examination
20 y from
filing*
- Can be broad
- 20 y
- Good trade asset
- Expensive
- Technical feature required
- Long time procedure
Patent protection
Copyright, trademark
Database protection
Copyright on software
BUSINESS DEVELOPMENT
.
IOF-Advanced Innovation mandate Baekeland mandate
SBO-project IOF-starTT IOF-Advanced IOF-Stepstone + Spin-off mandate
SBO-project TBM -project
Oprit E40
Gro
te S
teenw
eg N
oord
Schaarkensstraat
Tramstraat
Gew
estweg N
469
E40 Oostende - Brussel
HERTOOIEBOS
ELINTEC
TOEGANG
TRAMSTRAAT
Tramstraat
VIB Bio
Incubator
(7.500 m2)
E2S
IIC incubator
(3.600 + 600 m2)
Technology Park
Bio Accelerator
10.000 + 6.000m2
Materials cluster
Biotech cluster
ICT cluster
ICT Research
Building
COURSES
TT-Skills
1/year: November
5 days in 5 weeks (1 day a week: usually Wednesday)
General Topics: Funding, Contracts, IPR, Business development
For postdocs, Phd (3years experience), ZAP, new TT or IOF
Advanced courses
Usually April-May
2 till 5 days
Specialized topics: Marketing, Financing, Spin-offs,
For postdocs with concrete spin-off ideas
47
BEFORE YOU TALK TO 3TH PARTIES,
TALK TO US.
UZGENT
Health, Innovation and Research Institute
49
Innovation and Valorisation Unit
Lieve Nuytinck: Advisor valorisation
Tel. +32 9 332 05 32
lieve.nuytinck@ugent.be
IOF-CONSORTIA (BUSINESS DEVELOPMENT CENTERS)
life science
Protein
Tech
MedTeg
IOF-CONSORTIA
51
Daisy.Flamez@UGent.be
Biomarker pre-clinical research for
diagnostics and targeted therapies, oncology,
diabetes, HIV and ageing diseases,
Drug discovery, drug delivery
and drug manufacturing
Dominic.degroote@UGent.be
MedTeg
Medical device
technology
Ewout.vansteenkiste@ugent.be
Hybrid CT image building
technologies for material and
life science applications
TECHTRANSFER
52
UGent TechTransfer
Zwijnaarde Technologiepark 15
3th floor
Gent-Zwijnaarde
contracten@ugent.be
octrooien@ugent.be
techtransfer@ugent.be
Tech Transfer Office
IOF Project Funding Contract
Management IP Management
Business
Development
Network of Industrial Liaison Units
UGENT TECHTRANSFER
IOF / IRF
ConcepTT
StartTT
Advanced
Stepstone NDA or CDA, MTA
Service contracts
Research contracts
License agreements
I-Depot,
invention disclosure form
patent filing, patent search,
Other IPR
EU-funding, KIC-funding
FWO / VLAIO – funding
Spin-offs – incubation
Technology park
IOF@ugent.be
contracten@ugent.be
octrooien@ugent.be techtransfer@ugent.be
www.techtransfer.ugent.be
55
Success
Karen Curé Business Development
UGent Tech Transfer
E Karen.Cure@ugent.be
T +32 9 264 99 64
www.ugent.be/techtransfer
Ghent University
@ugenttt
Ghent University